Carl P. Sherr & Co. LLC Reduces Holdings in Johnson & Johnson $JNJ

Carl P. Sherr & Co. LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.0% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 10,030 shares of the company’s stock after selling 986 shares during the period. Carl P. Sherr & Co. LLC’s holdings in Johnson & Johnson were worth $1,532,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of JNJ. GFG Capital LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $35,000. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson in the first quarter worth $48,000. Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson in the first quarter worth $52,000. Finally, Pandora Wealth Inc. bought a new position in Johnson & Johnson in the first quarter worth $65,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.4%

NYSE:JNJ opened at $196.00 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a market cap of $472.22 billion, a P/E ratio of 18.92, a P/E/G ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $197.18. The firm has a 50-day simple moving average of $185.81 and a two-hundred day simple moving average of $169.94.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. Analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of a number of research reports. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a report on Monday, October 20th. The Goldman Sachs Group lifted their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Argus set a $210.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 15th. JPMorgan Chase & Co. raised their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Finally, Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $201.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.